Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / GILD - CymaBay's Seladelpar Is A Solid But Pricey Addition To Gilead's Liver Franchise

GILD - CymaBay's Seladelpar Is A Solid But Pricey Addition To Gilead's Liver Franchise

Gilead Sciences Inc.

2024-02-13 09:04:41 ET

Summary

  • Gilead Sciences' acquisition of CymaBay Therapeutics introduces seladelpar into its portfolio, expanding its presence in liver diseases.
  • Seladelpar shows clinical promise for PBC, with significant improvements in key liver health markers and pruritus relief.
  • Financially, the acquisition is earnings-neutral short term, with accretion expected post-2025, despite Gilead's significant debt.
  • Recommendation: Hold Gilead shares, monitoring seladelpar's market integration and Gilead's financial management post-acquisition.

At a Glance

For further details see:

CymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver Franchise
Stock Information
Company Name: Gilead Sciences Inc.
Stock Symbol: GILD
Market: NASDAQ
Website: gilead.com
Menu
GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board
Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...